Viking Therapeutics poised for major share price increase following new obesity data
The study achieves primary and all secondary endpoints, showing statistically significant reductions in body weight at all doses compared to placebo.
by MARKETWIRE
A potential future competitor in the booming obesity market has sent the shares of US biotech company Viking Therapeutics soaring by more than 100% in the US pre-market on Tuesday.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
